The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled

Cell Biochemistry and Function

Volumn 30, Issue 5, 2012, Pages 355-375

  Rowe, Peter S N ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

ASARM; DMP1; FGF23; KLOTHO; MEPE; PHEX

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; METALLOPROTEINASE; OVOCLEIDIN 116; PHOSPHATE REGULATING GENE WITH HOMOLOGIES TO ENDOPEPTIDASES ON THE X CHROMOSOME PROTEIN; PHOSPHOPROTEIN; SMALL INTEGRIN BINDING LIGAND INTERACTING GLYCOPROTEIN; UNCLASSIFIED DRUG;

BONE MINERALIZATION; ENERGY METABOLISM; HUMAN; HYPOPHOSPHATEMIC RICKETS; KIDNEY CALCIFICATION; NONHUMAN; OSSIFICATION; OSTEOMALACIA; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; EGG PROTEINS; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; OSTEOGENESIS; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHATES;

AVES; MUS; VERTEBRATA;

EID: 84863314939     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2841     Document Type: Review

References (219)

1. Tian X, Gautron J, Monget P, Pascal G. What makes an egg unique? Clues from evolutionary scenarios of egg-specific genes. Biol Reprod 2010; 83(6): 893-900.
2. Hincke MT, Gautron J, Tsang CP, McKee MD, Nys Y. Molecular cloning and ultrastructural localization of the core protein of an eggshell matrix proteoglycan, ovocleidin-116. J Biol Chem 1999; 274(46): 32915-32923.
3. Opsahl Vital S, Gaucher C, Bardet C, et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 2012; 50(4): 989-997.
4. Bardet C, Vincent C, Lajarille MC, Jaffredo T, Sire JY. OC-116, the chicken ortholog of mammalian MEPE found in eggshell, is also expressed in bone cells. J Exp Zool B Mol Dev Evol 2010; 314(8): 653-662.
5. Bardet C, Delgado S, Sire JY. MEPE evolution in mammals reveals regions and residues of prime functional importance. Cell Mol Life Sci 2010; 67(2): 305-320.
6. Horvat-Gordon M, Yu F, Burns D, Leach RM, Jr. Ovocleidin (OC 116) is present in avian skeletal tissues. Poult Sci 2008; 87(8): 1618-1623.
7. Consortium ICS. Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution. Nature 2004; 432(7018): 695-716.
8. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003; 44(Suppl 1): 33-40.
9. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67(1): 54-68.
10. Rowe PSN. The wrickkened-pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 2004; 15(5): 264-281.
11. Kawasaki K. The SCPP gene family and the complexity of hard tissues in vertebrates. Cells Tissues Organs 2011; 194(2-4): 108-112.
12. Kawasaki K, Weiss KM. Evolutionary genetics of vertebrate tissue mineralization: the origin and evolution of the secretory calcium-binding phosphoprotein family. J Exp Zoolog B Mol Dev Evol 2006; 306(3): 295-316.
13. Econs MJ, Francis F, Rowe PSN, et al. Dinucleotide repeat polymorphism at the DXS1683 locus. Hum Mol Genet 1994; 3(4): 680.
14. Francis F, Strom TM, Hennig S, et al. Genomic organisation of the human PEX gene mutated in X-linked dominant hypophosphataemic rickets. Gen Res 1997; 7(6): 573-585.
15. Rowe PSN. Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 1994; 94(5): 457-467.
16. Rowe PSN. The role of the PHEX gene (PEX), in families with X-linked hypophosphataemic rickets. Curr Opin Nephrol Hypertens 1998; 7(4): 367-376.
17. Rowe PSN. Finding mutations in disease genes. In Genetics of Osteoporosis and Metabolic Bone Disease. 1 ed. Econs MJ (ed.). Totowa New Jersey: Humana Press Inc; 2000; 431-446.
18. Rowe PSN, Francis F, Goulding J. Rapid isolation of DNA sequences flanking microsatellite repeats. Nucleic Acids Res 1994; 22(23): 5135-5136.
19. Rowe PSN, Goulding J, Read A, et al. refining the genetic-map for the region flanking the x-linked hypophosphatemic rickets locus (xp22.1-22.2). Hum Genet 1994; 93(3): 291-294.
20. Rowe PSN, Goulding J, Read AP, et al. New markers for linkage analysis of hypophosphataemic rickets. Hum Genet 1993; 91: 571-575.
21. Rowe PSN, Goulding JN, Francis F, et al. The gene for X-linked hypophosphataemic rickets maps to a 200-300kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet 1996; 97(3): 345-352.
22. Rowe PSN, Oudet C, Francis F, et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 1997; 6: 539-549.
23. Rowe PSN, Read AP, Mountford RC, et al. Three DNA markers for hypophosphataemic rickets. Hum Genet 1992; 89: 539-542.
24. HYP-consortium, Francis F, Hennig S, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11(2): 130-136.
25. Rowe PSN, Ong A, Cockerill F, Goulding J, Hewison M. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphataemic osteomalacia. Bone 1996; 18(2): 159-169.
26. Bianchetti L, Oudet C, Poch O. M13 endopeptidases: new conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish. Proteins 2002; 47(4): 481-188.
27. Rawlings ND, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 1999; 27: 325-331.
28. Turner AJ. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans 2003; 31(Pt 3): 723-727.
29. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 2001; 23(3): 261-269.
30. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007; 192(1): 261-267.
31. Martin A, David V, Laurence JS, et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008; 149(4): 1757-1772.
32. Rowe PSN, Garrett IR, Schwarz PM, et al. Surface Plasmon Resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005; 36(1): 33-46.
33. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009; 4(3): 363-371.
34. Addison W, Masica D, Gray J, McKee MD. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 2009; 25(4): 695-705.
35. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009; 150(9): 4012-4023.
36. Campos M, Couture C, Hirata IY, et al. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 2003; 373(1): 271-279.
37. Addison W, Nakano Y, Loisel T, Crine P, McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite - an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008; 23(10): 1638-1649.
38. Rowe PS, Matsumoto N, Jo OD, et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006; 39(4): 773-786.
39. Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res 2011; 27(7): 1425-1436.
40. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD. Inhibition of MEPE cleavage by PHEX. Biochem Biophys Res Commun 2002; 297(1): 38-45.
41. Rowe PSN, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004; 34(2): 303-319.
42. David V, Martin AC, Hedge AM, Drezner MK, Rowe PS. ASARM peptides: PHEX-dependent & independent regulation of serum phosphate. Am J Physiol Renal Physiol 2011; 300(3): F783-91.
43. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 2008; 23(2): 730-733.
44. Marks J, Churchill LJ, Edward SD, Unwin R. The phosphatonin matrix extracellular phosphoglycoprotein (MEPE) inhibits renal intestinal phosphate transport in vivo. J Am Soc Nephrol 2008; 19(12): 2313-2320.
45. Shirley DG, Faria NJ, Unwin RJ, Dobbie H. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol Dial Transplant 2010; 25(10): 3191-315.
46. Friedlander G. Welcome to MEPE in the renal proximal tubule. Nephrol Dial Transplant 2010; 25(10): 3135-3136.
47. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 2001; 60(1): 77-82.
48. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165(899): 1264-1266.
49. Goobes R, Goobes G, Shaw WJ, Drobny GP, Campbell CT, Stayton PS. Thermodynamic roles of basic amino acids in statherin recognition of hydroxyapatite. Biochemistry 2007; 46(16):4725-4733 Epub 2007 Mar 29.
50. Schlesinger DH, Hay DI. Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva. J Biol Chem 1977; 252(5): 1689-1695.
51. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38(11): 1310-1315.
52. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38(11): 1248-1250.
53. Gowen LC, Petersen DN, Mansolf AL, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003; 278(3): 1998-2007.
54. Zmuda JM, Yerges-Armstrong LM, Moffett SP, et al. Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men. Osteoporos Int 2011; 22(4): 1079-1090.
55. Jemtland R, Holden M, Reppe S, et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011; 26(8): 1793-1801.
56. Styrkarsdottir U, Halldorsson BV, Gudbjartsson DF, et al. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS One 2010; 5(10):e13217. PMCID: 2951352.
57. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009; 41(11): 1199-1206.
58. Kulkarni RN, Bakker AD, Everts V, Klein-Nulend J. Inhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE. Calcif Tissue Int 2010; 87(5):461-468. PMCID: 2964475.
59. Gluhak-Heinrich J, Pavlin D, Yang W, MacDougall M, Harris SE. MEPE expression in osteocytes during orthodontic tooth movement. Arch Oral Biol 2007; 52(7):684-690. PMCID: 1868431.
60. Hayashibara T, Hiraga T, Sugita A, et al. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 2007; 22(11): 1743-1751.
61. Harris SE, Gluhak-Heinrich J, Harris MA, et al. DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: theoretical role in controlling mineral quality in the perilacunar matrix. J Musculoskelet Neuronal Interact 2007; 7(4): 313-315.
62. Nampei A, Hashimoto J, Hayashida K, et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 2004; 22(3): 176-184.
63. Amir LR, Jovanovic A, Perdijk FB, Toyosawa S, Everts V, Bronckers AL. Immunolocalization of SIBLING and RUNX2 proteins during vertical distraction osteogenesis in the human mandible. J Histochem Cytochem 2007; 55(11): 1095-1104.
64. Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab 2009; 20(5): 230-236.
65. Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 2009; 89(1): 7-14.
66. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009; 310(1-2): 21-9.
67. David V, Martin A, Hedge AM, Rowe PS. PHEX & MEPE ASARM-motif regulate a novel bone-renal and fat-mass pathway (abstract). J Bone Miner Res 2009; 24(Suppl 1): Abstract:.
68. Petersen DN, Tkalcevic GT, Mansolf AL, Rivera-Gonzalez R, Brown TA. Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem 2000; 275(46): 36172-36180.
69. Argiro L, Desbarats M, Glorieux FH, Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 2001; 74(3): 342-351.
70. Butler WT, Bhown M, Brunn JC, et al. Isolation, characterization and immunolocalization of a 53-kDal dentin sialoprotein (DSP). Matrix 1992; 12(5): 343-351.
71. Ritchie HH, Hou H, Veis A, Butler WT. Cloning and sequence determination of rat dentin sialoprotein, a novel dentin protein. J Biol Chem 1994; 269(5): 3698-3702.
72. Linde A, Bhown M, Butler WT. Noncollagenous proteins of dentin. A re-examination of proteins from rat incisor dentin utilizing techniques to avoid artifacts. J Biol Chem 1980; 255(12): 5931-5942.
73. MacDougall M, Simmons D, Luan X, Nydegger J, Feng J, Gu TT. Dentin phosphoprotein and dentin sialoprotein are cleavage products expressed from a single transcript coded by a gene on human chromosome 4. Dentin phosphoprotein DNA sequence determination. J Biol Chem 1997; 272: 835-842.
74. Ritchie HH, Wang LH. Sequence determination of an extremely acidic rat dentin phosphoprotein. J Biol Chem 1996; 271(36): 21695-21698.
75. Yamakoshi Y, Hu JC, Fukae M, Zhang H, Simmer JP. Dentin glycoprotein: the protein in the middle of the dentin sialophosphoprotein chimera. J Biol Chem 2005; 280(17): 17472-17479.
76. Tsuchiya S, Simmer JP, Hu JC, Richardson AS, Yamakoshi F, Yamakoshi Y. Astacin proteases cleave dentin sialophosphoprotein (Dspp) to generate dentin phosphoprotein (Dpp). J Bone Miner Res 2011; 26(1): 220-228.
77. Bresler D, Bruder J, Mohnike KL, Fraser D, Rowe PSN. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004; 183: R1-9.
78. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001; 280(2): 460-465.
79. Machado JP, Johnson WE, O'Brien SJ, Vasconcelos V, Antunes A. Adaptive evolution of the matrix extracellular phosphoglycoprotein in mammals. BMC Evol Biol 2011; 11(1): 342.
80. Wang HG, Kawashima N, Iwata T, et al. MEPE activated by furin promotes pulpal cell adhesion. J Dent Res 2011; 90(4): 529-534.
81. Sprowson AP, McCaskie AW, Birch MA. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res 2008; 26(9): 1256-1262.
82. Gaucher C, Boukpessi T, Septier D, et al. Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets. Cells Tissues Organs 2009; 189(1-4): 219-223.
83. Nagel DE, Khosla S, Sanyal A, Rosen DM, Kumagai Y, Riggs BL. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem 2004; 93(6): 1107-1114.
84. Goldberg M, Lacerda-Pinheiro S, Jegat N, et al. The impact of bioactive molecules to stimulate tooth repair and regeneration as part of restorative dentistry. Dent Clin North Am 2006; 50(2): 277-298.
85. Liu H, Li W, Gao C, Kumagai Y, Blacher RW, DenBesten PK. Dentonin, a fragment of MEPE, enhanced dental pulp stem cell proliferation. J Dent Res 2004; 83(6): 496-499.
86. Six N, Septier D, Chaussain-Miller C, Blacher R, DenBesten P, Goldberg M. Dentonin, a MEPE fragment, initiates pulp-healing response to injury. J Dent Res 2007; 86(8): 780-785.
87. Chen S, Chen L, Jahangiri A, et al. Expression and processing of small integrin-binding ligand N-linked glycoproteins in mouse odontoblastic cells. Arch Oral Biol 2008; 53(9):879-889.
88. Boskey AL. Osteopontin and related phosphorylated sialoproteins: effects on mineralization. Ann N Y Acad Sci 1995; 760: 249-256.
89. Boskey AL, Chiang P, Fermanis A, et al. MEPE's diverse effects on mineralization. Calcif Tissue Int 2010; 86(1): 42-46.
90. Deshpande AS, Fang PA, Zhang X, Jayaraman T, Sfeir C, Beniash E. Primary structure and phosphorylation of dentin matrix protein 1 (DMP1) and dentin phosphophoryn (DPP) uniquely determine their role in biomineralization. Biomacromolecules 2011; 12(8):2933-2945. PMCID: 3171794.
91. Boukpessi T, Gaucher C, Leger T, et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol 2010; 177(2):803-12. PMCID: 2913338.
92. Boukpessi T, Septier D, Bagga S, Garabedian M, Goldberg M, Chaussain-Miller C. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int 2006; 79(5): 294-300.
93. Jiang B, Cao Z, Lu Y, et al. DMP1 C-terminal mutant mice recapture the human ARHR tooth phenotype. J Bone Miner Res 2010; 25(10): 2155-2164.
94. Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 2005; 68(1): 155-166.
95. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95: 5372-5377.
96. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res 2003; 18(4): 644-657.
97. Gupta A, Tenenhouse HS, Hoag HM, et al. Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice. Bone 2001; 29(5): 467-476.
98. Tenenhouse HS, Gauthier C, Chau H, St-Arnaud R. 1{alpha}-Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted Na/Pi cotransporter gene Npt2a. Am J Physiol Renal Physiol 2003; 286(4): F675-681.
99. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47(3): 312-318.
100. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 2004; 109(16): 1933-1927.
101. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13(2): 189-197.
102. Asaba Y, Ito M, Fumoto T, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 2008; 24(3): 241-250.
103. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22(7):2465-2475. Epub 008 Feb 6.
104. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22(9):1603-1609. PMCID: 3171931.
105. Yuan B, Takaiwa M, Clemens TL, et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008; 118(2): 722-734.
106. Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25(8): 2551-2562.
107. Wu H, Teng PN, Jayaraman T, et al. Dentin matrix protein 1 (DMP1) signals via cell surface integrin. J Biol Chem 2011; 286(34):29462-29469. PMCID: 3190986.
108. Eapen A, Ramachandran A, Pratap J, George A. Activation of the ERK1/2 mitogen-activated protein kinase cascade by dentin matrix protein 1 promotes osteoblast differentiation. Cells Tissues Organs. 2011; 194(2-4):255-260. PMCID: 3178087.
109. Yuan B, Bowman S, Blank R, Lindberg I, Drezner MK. Mechanism of hexa-D-arginine curative effects on the HYP phenotype (abstract). J Bone Miner Res 2011; 26(Suppl 1):SA0032:.
110. Yuan B, Meudt J, Blank R, Feng J, Drezner MK. Hexa-D-arginine reversal of osteoblast 7B2 dysregulation in HYP-mice normalizes the HYP biochemical phenotype (abstract). J Bone Miner Res 2010; 25(Suppl 1):(Presentation No: #1015).
111. Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry 2008; 47(22):5986-5995. PMCID: 2484124.
112. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin-binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004; 18(6): 734-736.
113. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(12): 4060-4066.
114. Karadag A, Fedarko NS, Fisher LW. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 2005; 65(24):11545-11552. PMCID: 1350722.
115. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004; 96(12): 956-965.
116. Eapen AS, Ramachandran A, George A. DPP activates integrin-mediated anchorage-dependent signals in undifferentiated mesenchymal cells. J Biol Chem 2011; 287(8): 5211-5224.
117. Bleicher F, Couble ML, Buchaille R, Farges JC, Magloire H. New genes involved in odontoblast differentiation. Adv Dent Res 2001; 15: 30-33.
118. Nakashima M, Iohara K, Ishikawa M, et al. Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (GDF11). Hum Gene Ther 2004; 15(11): 1045-1053.
119. Alos N, Ecarot B. Downregulation of osteoblast PHEX expression by PTH. Bone 2005; 37(4): 589-598.
120. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150(11): 4835-4845.
121. Narayanan K, Ramachandran A, Hao J, He G, Park KW, Cho M, George A. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem 2003; 278(19): 17500-17508.
122. Yuan B, Lin S, Cao Z, et al. DMP1 does not function as a co-transcriptional factor (abstract). J Bone Miner Res 2011; 26(Suppl 1): MO0112.
123. Matsumoto N, Jo OD, Shih RN, et al. Increased cathepsin D release by HYP mouse osteoblast cells. Am J Physiol Endocrinol Metab 2005; 289(1): E123-132.
124. Matsumoto N, Jo OD, Shih RN, Yanagawa N. Altered cathepsin D metabolism in PHEX antisense human osteoblast cells. Biochem Biophys Res Commun 2005; 332(1): 248-253.
125. Shih NR, Jo OD, Yanagawa N. Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol 2002; 13(2): 394-399.
126. Cho YD, Yoon WJ, Woo KM, et al. Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2. J Biol Chem 2009; 284(37): 25230.
127. Yang W, Harris SE, Raw P, Feng J, Gluhak-Heinrich J. MEPE over-expression in osteocytes of DMP1 null mice by activation of the PKA/CREB pathway. J Bone Miner Res 2006; 21: S136-S.
128. Gluhak-Heinrich J, Yang W, Bonewald LF, Robling AG, Turner CH, Harris SE. Mechanically induced DMP1 and MEPE expression in osteocytes: correlation to mechanical strain, osteogenic response and gene expression threshold. J Bone Miner Res 2005; 20(9): S73-S.
129. Gluhak-Heinrich J, Ye L, Bonewald LF, et al. Mechanical loading stimulates dentin matrix protein 1 (DMP1) expression in osteocytes in vivo. J Bone Miner Res 2003; 18(5): 807-817.
130. McKee MD, Nanci A. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat Rec 1996; 245(2): 394-409.
131. Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 2011; 26(11): 2634-2646.
132. Tu X, Rhee Y, Condon K, et al. Sost downregulation and local WNT signaling are required for the osteogenic response to mechanical loading. Bone 2011; 50(11): 209-217.
133. Lu Y, Yuan B, Qin C, et al. The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa c-terminal fragment. J Bone Miner Res 2011; 26(2): 331-340.
134. Prie D, Torres PU, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009; 4: 1-8.
135. Alvarez-Diaz S, Larriba MJ, Lopez-Otin C, Munoz A. Vitamin D: proteases, protease inhibitors and cancer. Cell Cycle 2010; 9(1): 32-37.
136. Bao BY, Yeh SD, Lee YF. 1alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006; 27(1): 32-42.
137. Brage M, Abrahamson M, Lindstrom V, Grubb A, Lerner UH. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int 2005; 76(6): 439-447.
138. Danjo A, Yamaza T, Kido MA, et al. Cystatin C stimulates the differentiation of mouse osteoblastic cells and bone formation. Biochem Biophys Res Commun 2007; 360(1): 199-204.
139. Lenarcic B, Kos J, Dolenc I, Lucovnik P, Krizaj I, Turk V. Cathepsin D inactivates cysteine proteinase inhibitors, cystatins. Biochem Biophys Res Commun 1988; 154(2): 765-772.
140. Nishimura Y, Kawabata T, Kato K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 1988; 261(1): 64-71.
141. Dubois SG, Ruchon AF, Delalandre A, Boileau G, Lajeunesse D. Role of abnormal neutral endopeptidase-like activities in HYP mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol 2002; 283(5): C1414-1421.
142. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 1985; 75: 1858-1868.
143. Marie PJ, Travers R, Glorieux FH. Healing of bone lesions with 1, 25-dihydroxyvitamin D3 in the young X-linked hypophosphataemic male mouse. Endocrinology 1982; 111: 904-911.
144. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010;95(4):1846-1850. PMCID: 2853995.
145. Hoffman WH, Jain A, Chen H, Fedarko NS. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A 2008; 146A(16): 2164-2168.
146. Bonjour JP, Trechsel U, Fleisch H, Schenk R, DeLuca HF, Baxter LA. Action of 1, 25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats. Am J Physiol 1975; 229(2): 402-408.
147. Lawson-Matthew PJ, Guilland-Cumming DF, Yates AJ, Russell RG, Kanis JA. Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man. Clin Sci (Lond) 1988; 74(1): 101-106.
148. Loghman-Adham M, Dousa TP. Dual action of phosphonoformic acid on Na(+)-phosphate cotransport in opossum kidney cells. Am J Physiol 1992; 263(2 Pt 2): F301-10.
149. Loghman-Adham M, Szczepanska-Konkel M, Dousa TP. Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid. J Am Soc Nephrol 1992; 3(6): 1253-1259.
150. Loghman-Adham M, Szczepanska-Konkel M, Yusufi AN, Van Scoy M, Dousa TP. Inhibition of Na + -Pi cotransporter in small gut brush border by phosphonocarboxylic acids. Am J Physiol 1987; 252(2 Pt 1): G244-9.
151. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8(Suppl 1): S35-41.
152. McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J, Kanis JA. Diphosphonates and phosphate homeostasis in man. Clin Sci (Lond) 1988; 74(6): 607-612.
153. Muhlbauer RC, Bonjour JP, Fleisch H. Tubular handling of phosphate along the nephron of thyroparathyroidectomized rats injected with ethane-1-hydroxy-1, 1-diphosphonate. Clin Sci (Lond) 1981; 60(2): 171-177.
154. Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 1975; 49(1): 45-56.
155. Stoll R, Fleisch H, Bonjour JP. Effect of diphosphonate treatment on phosphate transport by renal brush border vesicles. Am J Physiol 1980; 239(1): F13-16.
156. Szczepanska-Konkel M, Yusufi ANK, VanScoy M, Webster SK, Dousa TP. Phosphonocarboxylic acids as specific inhibitors of Na+- dependent transport of phosphate across renal brush border membrane. J Biol Chem 1986; 261: 6375-6383.
157. Trechsel U, Schenk R, Bonjour JP, Russell RG, Fleisch H. Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats. Am J Physiol 1977; 232(3): E298-305.
158. VanScoy M, Loghman-Adham M, Onsgard M, et al. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol 1988; 255(5 Pt 2): F984-994.
159. Baum M, Moe OW, Zhang J, Dwarakanath V, Quigley R. Phosphatonin washout in HYP mice proximal tubules: evidence for posttranscriptional regulation. Am J Physiol Renal Physiol 2005; 288(2):F363-370 Epub 2004 Sep 28.
160. Nesbitt T, Byun JK, Drezner MK. Normal phosphate transport in cells from the S2 and S3 segments of HYP-mouse proximal renal tubules. Endocrinology 1996; 137: 943-948.
161. Nesbitt T, Econs MJ, Byun JK, Martel J, Tenenhouse HS, Drezner MK. Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and HYP mice: evidence that the HYP gene locus product is an extrarenal factor. J Bone Miner Res 1995; 10: 1327-1333.
162. Szczepanska-Konkel M, Yusufi AN, Dousa TP. Interactions of [14C]phosphonoformic acid with renal cortical brush-border membranes. Relationship to the Na+-phosphate co-transporter. J Biol Chem 1987; 262(17): 8000-8010.
163. Ullrich KJ, Rumrich G, Burke TR, Shirazi-Beechey SP, Lang H. Interaction of alkyl/arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther 1997; 283(3): 1223-1229.
164. Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci 2010; 1192: 190-200.
165. Ecarot B, Desbarats M. 1, 25-(OH)(2)D-3 down-regulates expression of PHEX, a marker of the mature osteoblast. Endocrinology 1999; 140(3): 1192-1199.
166. Hines ER, Kolek OI, Jones MD, et al. 1, 25-dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem 2004; 279(45): 46406-46414.
167. Steiglitz BM, Ayala M, Narayanan K, George A, Greenspan DS. Bone morphogenetic protein-1/tolloid-like proteinases process dentin matrix protein-1. J Biol Chem 2004; 279(2): 980-986.
168. von Marschall Z, Fisher LW. Dentin matrix protein-1 isoforms promote differential cell attachment and migration. J Biol Chem. 2008; 283(47):32730-40. PMCID: 2583300.
169. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135(5):825-37. PMCID: 2614332.
170. Yadav VK, Oury F, Tanaka K, et al. Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications. J Exp Med 2011; 208(1): 41-52.
171. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 2008; 19(5): 161-166.
172. Goltzman D. LRP5, serotonin and bone: complexity, contradictions and conundrums. J Bone Miner Res 2011; 26(9): 2002-2011.
173. Cui Y, Niziolek PJ, Macdonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011; 17(6):684-691. PMCID: 3113461.
174. Price S. Bone: evidence for local effects of LRP5 on bone mass. Nat Rev Rheumatol 2011; 7(7): 373.
175. Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol 2010; 191(1):7-13. PMCID: 2953449.
176. Ducy P. 5-HT and bone biology. Curr Opin Pharmacol 2011; 11(1): 34-38.
177. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 2011; 26(4): 677-680.
178. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66(2): 236-253.
179. Ubaidus S, Li M, Sultana S, et al. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo) 2009; 58(6): 381-392.
180. Rowe PS, Hedge AM, David V, Zelenchuk L. PHEX and fat energy metabolism across a bone-renal axis (abstract). J Bone Miner Res 2011; 26(Suppl 1): Abstract:.
181. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119(1): 84-90.
182. Cade C, Norman AW. Rapid normalization/stimulation by 1, 25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology 1987; 120(4): 1490-1497.
183. Capparelli AW, Roh D, Dhiman JK, Jo OD, Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology 1992; 130(1): 328-334.
184. Hruska KA, Rifas L, Cheng SL, Gupta A, Halstead L, Avioli L. X-linked hypophosphatemic rickets and the murine HYP homologue. Am J Physiol 1995; 268:F357-F62.
185. Rifas L, Cheng S, Halstead LR, Gupta A, Hruska KA, Avioli LV. Skeletal casein kinase activity defect in the HYP mouse. Calcif Tissue Int 1997; 61: 256-259.
186. Rifas L, Gupta A, Hruska KA, Avioli LV. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif Tissue Int 1995; 57(1): 60-63.
187. Xie W, Mechin MC, Dubois SG, Lajeunesse D, van de Werve G. Up-regulation of liver glucose-6-phosphatase in X-linked hypophosphatemic mice. Horm Metab Res 2002; 34(6): 288-292.
188. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17(3): 509-511.
189. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26(2): 20.
190. Utsugi T, Ohno T, Ohyama Y, et al. Decreased insulin production and increased insulin sensitivity in the KLOTHO mutant mouse, a novel animal model for human aging. Metabolism 2000; 49(9): 1118-1123.
191. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390(6655): 45-51.
192. Lorenzi O, Veyrat-Durebex C, Wollheim CB, et al. Evidence against a direct role of KLOTHO in insulin resistance. Pflugers Arch 2009; 459(3): 465-473.
193. Drueke TB. KLOTHO, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int 2010; 78(11): 1057-60.
194. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53(5): 875-883.
195. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24(2): 382-391.
196. Kurokawa K, Rasmussen H. Ionic control of renal gluconeogenesis. IV. Effect of extracellular phosphate concentration. Biochim Biophys Acta 1973; 313(1): 59-71.
197. Paula FJ, Plens AE, Foss MC. Effects of hypophosphatemia on glucose tolerance and insulin secretion. Horm Metab Res 1998; 30(5): 281-4.
198. DeFronzo RA, Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med 1980; 303(22): 1259-1263.
199. Xie W, Li Y, Mechin MC, Van De Werve G. Up-regulation of liver glucose-6-phosphatase in rats fed with a P(i)-deficient diet. Biochem J 1999;343(Pt 2):393-6. PMCID: 1220566.
200. Xie W, Tran TL, Finegood DT, van de Werve G. Dietary P(i) deprivation in rats affects liver cAMP, glycogen, key steps of gluconeogenesis and glucose production. Biochem J 2000; 352(Pt 1):227-32. PMCID: 1221451.
201. Winther K, Nybo M, Vind B, Pedersen SM, Hojlund K, Rasmussen LM. Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients. Scand J Clin Lab Invest 2012; 72: 108-113.
202. Bateman RCJ, Hersh LB. Evidence for an essential histidine in neutral endopeptidase 24.11. Biochemistry 1987; 26: 4237-4242.
203. Beaumont A, Barbe B, Le Moual H, et al. Charge polarity reversal inverses the specificity of neutral endopeptidase-24.11. J Biol Chem 1992; 267(4): 2138-2141.
204. Kim YA, Shriver B, Quay T, Hersh LB. Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis. J Biol Chem 1992; 267(17): 12330-12335.
205. Sabbagh Y, Boileau G, Campos M, Carmona AK, Tenenhouse HS. Structure and function of disease-causing missense mutations in the PHEX gene. J Clin Endocrinol Metab 2003; 88(5): 2213-2222.
206. Sabbagh Y, Boileau G, DesGroseillers L, Tenenhouse HS. Disease-causingmissense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum Mol Genet 2001; 10(15): 1539-1546.
207. Sabbagh Y, Jones AO, Tenenhouse HS. PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum Mutat 2000; 16(1): 1-6.
208. Duret L, Gasteiger E, Perriere G. LALNVIEW: a graphical viewer for pairwise sequence alignments. Comput Appl Biosci 1996; 12: 507-510.
209. Huang X, Miller W, Schwartz S, Hardison RC. Parallelization of a local similarity algorithm. Comput Appl Biosci 1992; 8: 155-165.
210. Huang XQ, Hardison RC, Miller W. A space-efficient algorithm for local similarities. Comput Appl Biosci 1990; 6: 373-381.
211. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011; 8(10): 785-786.
212. Rice P. Programme Manual for the EGCG package. Hinxton Hall: Cambridge, CB10 1RQ, England, 1995.
213. Goldberg M, Six N, Chaussain C, DenBesten P, Veis A, Poliard A. Dentin extracellular matrix molecules implanted into exposed pulps generate reparative dentin: a novel strategy in regenerative dentistry. J Dent Res 2009; 88(5): 396-399.
214. Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004; 19(3): 455-462.
215. Vordemvenne T, Paletta JR, Hartensuer R, Pap T, Raschke MJ, Ochman S. Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts. BMC Musculoskelet Disord 2011; 12(1): 263.
216. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008; 105(13):5266-70. PMCID: 2278202.
217. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010; 142(2):296-308. PMCID: 2910411.
218. Karsenty G, Oury F. The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab 2010; 95(11): 4795-4801.
219. Zhou XJ, Fadda GZ, Perna AF, Massry SG. Phosphate depletion impairs insulin secretion by pancreatic islets. Kidney Int 1991; 39(1): 120-128.